HBK Sorce Advisory LLC Raises Holdings in Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC increased its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 19.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 203,705 shares of the biotechnology company’s stock after purchasing an additional 33,128 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Capricor Therapeutics were worth $5,879,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at $36,000. Russell Investments Group Ltd. grew its holdings in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares in the last quarter. GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at $59,000. Tower Research Capital LLC TRC grew its holdings in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new stake in Capricor Therapeutics in the 3rd quarter valued at $91,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at $247,758.99. This represents a 75.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the company’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 172,529 shares of company stock worth $5,302,440. Corporate insiders own 9.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Piper Sandler restated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Roth Mkm restated a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a report on Friday, May 15th. B. Riley Financial upped their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.36.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $28.87 on Monday. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The business’s fifty day simple moving average is $31.68 and its 200-day simple moving average is $25.14. The firm has a market cap of $1.67 billion, a PE ratio of -12.44 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts expect that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.